Access cutting-edge breast cancer treatment through this phase 1 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Philadelphia location
Preparing your pre-screening questions…
Access breast cancer specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related breast cancer treatment provided free
Check if you qualify for this breast cancer clinical trial in Philadelphia, PA
No-Cost Study Care
Local to Philadelphia
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.0 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 40 evaluable subjects will participate in a single imaging cohort. Patients will be stratified for analysis by breast cancer subtype with prioritization to recruit at least 10 estrogen-receptor-expressing (ER+) and 10 triple-negative breast cancers (TNBC). Participants may be treatment naïve or have received up to 3 weeks of treatment at the time of the \[18F\]F-Gln PET/CT scan. This is an observational study; \[18F\]F-GLN PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the \[18F\]F-GLN PET/CT results, treatment decisions are made by the treating physicians based upon clinical criteria. \[18F\]F-GLN PET/CT imaging sessions will include an injection of \[18F\]F-GLN. Metabolism data will be collected. Pilot data will be collected to evaluate image quality and collect preliminary information on the uptake of \[18F\]F-GLN in breast cancer. Uptake measures will be compared to tumor markers of glutamine metabolism, when tissue is available. The safety of \[18F\]F-GLN will also be evaluated in all subjects.
Sponsor: Abramson Cancer Center at Penn Medicine
Yes, this clinical trial (NCT03863457) has an active research site in Philadelphia, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for breast cancer treatment options in Philadelphia, PA, this clinical trial (NCT03863457) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.
See all breast cancer clinical trials recruiting in Philadelphia — not just this study.
Browse Breast Cancer Trials in Philadelphia →